🔍

ALKEM - Alkem Lab

📊 NSE: ALKEM 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 18:08

📢 Recent Corporate Announcements

Alkem Labs Receives EU GMP Compliance Certificate for Baddi Manufacturing Facility

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 14 Mar 2026, 03:45 PM

Alkem Laboratories has received a Certificate of GMP Compliance from the German Health Authority for its manufacturing plant located in Baddi, India. This certification follows a successful inspection conducted between November 4 and November 10, 2025. The certificate is valid for a period of three years from the date of inspection, ensuring the facility meets European standards for human medicines. This regulatory clearance is crucial for the company's ability to supply pharmaceutical products to the European market.

Received 'Certificate of GMP Compliance' from the Department of Pharmacy (Human Medicines) – Germany.
The inspection was conducted at the Baddi, India facility from 04th to 10th November 2025.
The compliance certificate is valid for a period of 3 years from the date of inspection.
The approval follows the initial inspection intimation provided by the company on 10th November 2025.

💡 Investors should view this as a positive development that de-risks the company's European export potential from the Baddi site. No immediate action is required, but this reinforces Alkem's strong regulatory compliance track record.

Alkem Labs Subsidiary Executes SPA to Acquire 51-55% Stake in Swiss Firm Occlutech Holding AG

🟢 POSITIVE ⭐ 9/10

M&A 📅 06 Mar 2026, 03:37 PM

Alkem Laboratories' subsidiary, Alkem Medtech, has officially signed a Share Purchase Agreement to acquire a controlling stake in Switzerland-based Occlutech Holding AG. The acquisition involves purchasing between 51% and 55% of the total issued equity share capital. This move follows the initial announcement made on February 13, 2026, signaling progress in Alkem's expansion into the medical technology sector. The transaction marks a significant step in Alkem's inorganic growth strategy in international markets.

Alkem Medtech to acquire a minimum of 51% and a maximum of 55% equity in Occlutech Holding AG
Occlutech Holding AG is a Swiss-incorporated company specializing in medical technology
The Share Purchase Agreement (SPA) was executed on March 06, 2026
The acquisition is being executed through Alkem's wholly-owned subsidiary, Alkem Medtech Private Limited

💡 Investors should view this as a strategic diversification into the high-growth medical devices segment. Monitor for future disclosures regarding the acquisition valuation and its impact on the company's consolidated debt and margins.

Alkem Laboratories Releases Strategic Roadmap Recording for MedTech Division

🔵 WATCH ⭐ 6/10

EXPANSION 📅 20 Feb 2026, 06:31 PM

Alkem Laboratories has officially released the video recording of its investor meet focused on the strategic way forward for Alkem MedTech. The disclosure, dated February 20, 2026, provides transparency into the company's future plans for its medical technology vertical. This meeting is significant as it outlines how the company intends to diversify beyond traditional pharmaceuticals. Investors can access the full recording via the company's website to evaluate the growth potential of this specific business segment.

Official recording of the 'Investor meet on Alkem MedTech’s strategic way forward' is now public.
The meeting focused specifically on the future growth drivers and strategy for the MedTech division.
Disclosure made in compliance with SEBI Listing Obligations and Disclosure Requirements (LODR) 2015.
Strategic updates for the MedTech arm indicate a focus on business diversification and long-term value creation.

💡 Investors should review the recording to understand the capital allocation and revenue expectations for the MedTech business. Monitor the segment's progress as a potential catalyst for valuation rerating beyond the core pharma business.

Alkem MedTech to Acquire 51-55% Stake in Occlutech Holding AG for €180.70 Million

🟢 POSITIVE ⭐ 9/10

M&A 📅 18 Feb 2026, 12:52 PM

Alkem Laboratories' subsidiary, Alkem MedTech, has executed a binding term sheet to acquire a majority stake (51-55%) in Occlutech Holding AG for an equity value of €180.70 million (approx. ₹19,516 million). Occlutech is a leading global player in the structural heart occluder market, ranking 2nd in Europe and 3rd globally, with 2025 net sales of €50 million. This acquisition provides Alkem with a robust global platform, including 200+ patents and a presence in high-barrier markets like the US, EU, and Japan. The transaction is expected to close by June 2026 and will be funded entirely through internal accruals and existing cash balances.

Acquisition of 51-55% stake in Occlutech Holding AG at an equity value of €180.70 million (₹19,516 million).
Occlutech reported €50 million in net sales for 2025 with a 14% CAGR from 2021-2025.
Strategic entry into the $680 billion global MedTech market, specifically targeting the high-margin cardiovascular and musculoskeletal segments.
Alkem MedTech aims for a 10% market share in the Indian large joints market within 5 years, targeting 250,000+ implants.
Transaction includes a strong R&D pipeline with US FDA approval for PFO occluders expected by June 2027.

💡 Investors should view this as a significant strategic pivot towards high-margin medical technology that diversifies Alkem's traditional pharma portfolio. Monitor the successful integration of Occlutech and the progress of US FDA approvals for their pipeline products as key valuation re-rating triggers.

Alkem Laboratories to Participate in Kotak and IIFL Investor Conferences in February 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 17 Feb 2026, 05:15 PM

Alkem Laboratories has announced its participation in two major institutional investor conferences scheduled for late February 2026. The company will attend the 'Kotak - Chasing Growth 2026' event on February 25 and the 'IIFL 17th Entrepreneurial India Conference' on February 26. Both events will feature in-person, one-on-one meetings held in Mumbai. These interactions are part of the company's routine engagement with the analyst community to discuss business prospects.

Scheduled one-on-one meeting at the Kotak - Chasing Growth 2026 conference on February 25, 2026.
Participation in the IIFL 17th Entrepreneurial India Conference 2026 on February 26, 2026.
Both investor interactions are scheduled to be held in-person in Mumbai.
Meetings are subject to change based on exigencies from the company or investors.

💡 Investors should watch for any investor presentations or transcripts released following these meetings for updates on the company's growth outlook. No immediate portfolio changes are recommended based on this routine disclosure.

Alkem Labs Q3 FY26 Revenue Up 10.7% to ₹3,737 Cr; Announces Strategic MedTech Acquisition

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 16 Feb 2026, 05:13 PM

Alkem Laboratories reported a steady Q3 FY26 with revenue growing 10.7% YoY to INR 37,368 million, driven by a robust 26.6% growth in international markets. The company announced a significant strategic entry into the MedTech space through the acquisition of Occlutech, targeting INR 1,000 crore in revenue from this segment within 3-5 years. While domestic growth was a modest 5.5% due to a high base effect, the company outperformed the Indian Pharmaceutical Market (IPM) in key therapies like anti-infectives and vitamins. EBITDA margins remained healthy at 22.2%, despite an exceptional charge of INR 528 million related to new labour codes.

Total revenue increased 10.7% YoY to INR 37,368 million, with international sales surging 26.6% to INR 12,157 million.
EBITDA grew 9% YoY to INR 8,280 million with a margin of 22.2%.
Management targets MedTech revenue of INR 1,000 crore with 25% EBITDA margins in the next 4-5 years.
Outperformed IPM in 6 therapies, notably growing 2x the market in Vitamins and 1.4x in Anti-infectives.
Net profit stood at INR 6,360 million, impacted by a INR 528 million exceptional item for Labour Code compliance.

💡 Investors should monitor the integration of the Occlutech acquisition as it represents a high-margin, technology-led growth lever for the company. The stock remains a strong play on domestic market leadership and expanding international footprint.

Alkem Subsidiary Enzene Receives USFDA Form 483 with 6 Observations for Pune Facility

🔵 WATCH ⭐ 7/10

REGULATORY 📅 16 Feb 2026, 03:03 PM

Alkem Laboratories' subsidiary, Enzene Biosciences, underwent a USFDA Pre-Approval Inspection (PAI) at its Chakan, Pune facility which concluded on February 13, 2026. The inspection resulted in the issuance of a Form 483 with 6 procedural observations. Importantly, the facility received zero observations related to data integrity, which is a critical metric for regulatory compliance. The company is currently preparing a response to address these observations within the stipulated timeline.

USFDA completed a Pre-Approval Inspection (PAI) at the Chakan, Pune facility on February 13, 2026
The inspection concluded with a Form 483 containing 6 procedural observations
Zero observations were reported regarding data integrity, validating the subsidiary's quality systems
Enzene Biosciences is a subsidiary of Alkem Laboratories Limited
The company has initiated corrective and preventive actions to address the USFDA's findings

💡 Investors should monitor the company's ability to resolve these 6 procedural observations promptly to secure final approval. The absence of data integrity issues is a positive sign, reducing the likelihood of more severe regulatory escalations like a Warning Letter.

USFDA Issues Form 483 with 6 Observations for Alkem Subsidiary Enzene Biosciences

🔵 WATCH ⭐ 7/10

REGULATORY 📅 14 Feb 2026, 12:02 PM

Alkem Laboratories' subsidiary, Enzene Biosciences, has completed a USFDA Pre-Approval Inspection (PAI) at its manufacturing facility in India. The inspection concluded with the issuance of a Form 483 containing 6 procedural observations. Crucially, the company reported zero observations related to data integrity, which is a positive indicator for the reliability of their quality systems. Enzene is currently preparing a formal response and has initiated corrective and preventive actions to address the findings.

USFDA completed a Pre-Approval Inspection (PAI) at Enzene Biosciences' Indian facility.
Form 483 issued with 6 procedural observations at the conclusion of the audit.
Zero observations reported regarding data integrity, validating the reliability of regulatory filings.
Company is preparing a response to be submitted within the stipulated timeline.
Corrective and preventive actions (CAPA) have already been initiated by the subsidiary.

💡 Investors should monitor for the final Establishment Inspection Report (EIR) to ensure these procedural observations do not escalate. The absence of data integrity issues is a significant positive that reduces the risk of severe regulatory sanctions.

Alkem Laboratories to Host Investor Meet for MedTech Strategy on Feb 18, 2026

🔵 WATCH ⭐ 6/10

EXPANSION 📅 13 Feb 2026, 08:01 PM

Alkem Laboratories has scheduled an investor meet for February 18, 2026, specifically to outline the strategic direction of Alkem MedTech. The meeting will involve senior leadership from both the parent company and the MedTech division to discuss future growth plans. This event is significant as it signals a focused push into the medical technology sector, which could diversify the company's revenue streams. Investors should watch for specific details on product development and market positioning during this session.

Investor meet scheduled for February 18, 2026, at 4:30 PM in Mumbai.
The primary agenda is to outline Alkem MedTech’s 'strategic way forward'.
Senior leadership from both Alkem Laboratories and Alkem MedTech will be present for the briefing.
The division focuses on 'Innovative, Affordable, and Accessible' medical technology solutions.

💡 Investors should monitor the post-event disclosures for specific capital expenditure plans and revenue guidance for the MedTech division. This vertical could be a key differentiator for Alkem's long-term valuation.

Alkem Laboratories to Outline MedTech Strategic Roadmap on February 18, 2026

🔵 WATCH ⭐ 6/10

EXPANSION 📅 13 Feb 2026, 07:35 PM

Alkem Laboratories has scheduled an investor meet for February 18, 2026, to specifically discuss the strategic direction of its MedTech division. The meeting will feature senior leadership from both the parent company and Alkem MedTech to present the 'strategic way forward.' This event is significant as it indicates a focused effort to scale the medical technology business, which could diversify the company's traditional pharmaceutical revenue base. Investors should monitor the session for details on product pipelines, market entry strategies, and capital expenditure plans for this segment.

Investor meet scheduled for February 18, 2026, at 4:30 PM IST in Mumbai.
The primary agenda is to outline Alkem MedTech’s strategic roadmap and future growth plans.
Senior leadership from both Alkem Laboratories and Alkem MedTech will be present to interact with institutional investors.
The session aims to highlight the company's focus on innovative, affordable, and accessible medical technology solutions.

💡 Investors should track the post-meet presentation or transcript to understand the scale of Alkem's MedTech ambitions and its projected contribution to the bottom line. This segment could be a long-term value unlock if the strategy demonstrates a clear path to high-margin growth.

Alkem MedTech to Acquire 55% Stake in Switzerland's Occlutech for INR 1,074 Crore

🟢 POSITIVE ⭐ 9/10

M&A 📅 13 Feb 2026, 02:38 PM

Alkem Laboratories' subsidiary, Alkem MedTech, has announced a binding offer to acquire a 55% majority stake in Swiss-based Occlutech Holding AG for approximately INR 1,074 crore (EUR 99.4 million). Occlutech is a leading global player in minimally invasive cardiac implants, ranking second in Europe and third globally. The company reported 2025 revenues of EUR 49.4 million with a 15.7% CAGR over the last three years, primarily from European and US markets. This acquisition marks Alkem's strategic entry into the high-barrier cardiovascular devices segment and significantly expands its global medical technology footprint.

Acquisition of up to 55% stake in Occlutech Holding AG for EUR 99.4 million (approx. INR 1,074 crore)
Occlutech is the 2nd largest company in Europe and 3rd globally in minimally invasive cardiac implants
Target company recorded revenue of EUR 49.4 million in 2025 with a 15.7% CAGR over three years
Provides immediate access to high-value regulated markets including the US, Japan, and Germany
Transaction is expected to be completed by June 2026 subject to regulatory approvals

💡 Investors should view this as a significant long-term growth driver that diversifies Alkem's revenue stream into high-margin medical technology. Monitor the progress of regulatory approvals and the subsequent integration of Occlutech's R&D capabilities.

Alkem Laboratories Revises Participant List for Q3FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Feb 2026, 02:17 PM

Alkem Laboratories has issued a revised intimation regarding its conference call for Q3FY26 and 9MFY26 financial results, scheduled for February 13, 2026, at 5:00 PM IST. The update specifically notes a change in the company representatives participating in the call. The management team will be represented by the Managing Director, the CFO, and the CEOs of both Alkem Laboratories and Alkem MedTech. This is a procedural update following the company's earlier communications on January 23 and February 12, 2026.

Conference call scheduled for February 13, 2026, from 5:00 PM to 6:00 PM IST.
Management participants include MD Sandeep Singh, CFO Nitin Agrawal, and CEO Dr. Vikas Gupta.
Kaustav Banerjee, CEO of Alkem MedTech, is also confirmed as a participant.
The call is hosted by Motilal Oswal Securities Ltd to discuss Q3 and 9MFY26 performance.

💡 This is a routine administrative update regarding call participants; investors should focus on the actual Q3FY26 financial results and management's outlook during the call.

Alkem Laboratories to Reopen Trading Window on February 16, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 13 Feb 2026, 02:14 PM

Alkem Laboratories has announced the reopening of its trading window for designated persons starting February 16, 2026. This follows the disclosure of the company's financial results for the quarter and nine months ended December 31, 2025, which were released on February 13, 2026. The trading window had been closed since December 30, 2025, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This is a standard procedural notification that occurs after every quarterly earnings cycle.

Trading window to officially reopen on February 16, 2026
Window was closed for 48 days starting from December 30, 2025
Reopening follows the announcement of Q3 and nine-month financial results on February 13, 2026
Compliance maintained under SEBI Prohibition of Insider Trading Regulations, 2015

💡 No action is required as this is a routine regulatory filing. Investors should focus on the financial performance details disclosed in the Q3 earnings report rather than this administrative update.

Alkem Labs Amends Saudi JV Agreement; Vitals Biotech to Hold 49% Stake

🟡 NEUTRAL ⭐ 4/10

EXPANSION 📅 13 Feb 2026, 02:09 PM

Alkem Laboratories has approved an amendment to its Shareholders' Agreement for a Joint Venture (JV) in Saudi Arabia, originally initiated in August 2025. While Alkem retains its 51% majority stake, the 49% minority stake will now be held by Vitals Biotech Company instead of the individual partner, Mr. Abdulaziz Alsheikh. This change is administrative, shifting the partner's ownership to a corporate entity he owns. The JV remains a key part of Alkem's international expansion strategy in the Middle East.

Alkem Laboratories to maintain a 51% controlling stake in the Saudi Arabian Joint Venture.
The 49% minority stake will be held by Vitals Biotech Company, a wholly owned company of the JV partner.
The amendment updates the original Shareholders' Agreement dated August 12, 2025.
The Board of Directors officially approved this structural change on February 13, 2026.

💡 This is a routine administrative update regarding the company's expansion into Saudi Arabia; investors should focus on the JV's operational progress and future revenue contributions.

Alkem Labs Approves Amendment for Saudi Arabia JV; Retains 51% Controlling Stake

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 13 Feb 2026, 02:06 PM

Alkem Laboratories has updated its Joint Venture (JV) plans in Saudi Arabia by amending the Shareholders' Agreement. The company will maintain a 51% majority stake in the new subsidiary, while the 49% partner stake will now be held by Vitals Biotech Company instead of an individual partner. This administrative change facilitates the company's strategic entry into the Middle Eastern pharmaceutical market. The board's approval on February 13, 2026, signals continued progress on this international expansion initiative.

Alkem Laboratories to hold a 51% majority stake in the Saudi Arabian Joint Venture.
JV partner stake of 49% transferred from Mr. Abdulaziz Alsheikh to his wholly-owned firm, Vitals Biotech Company.
Board of Directors approved the amendment to the Shareholders' Agreement on February 13, 2026.
The JV follows an initial agreement executed on August 12, 2025, for expansion into the Kingdom of Saudi Arabia.

💡 Investors should monitor the progress of this JV as it represents a key geographical diversification into the GCC region. No immediate action is required as this is an administrative update to a previously announced expansion plan.

View All ALKEM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue grew 2.3% YoY to INR 12,964.5 Cr in FY25. Domestic formulation sales grew 7% YoY in FY25, while US sales de-grew 15% in H1FY25 due to price erosion and supply chain issues. Rest of World (ROW) sales grew 33% in FY24 and 7% in H1FY25. In Q2 FY26, total revenue reached INR 4,001 Cr, a 17.2% YoY increase.

Geographic Revenue Split

The domestic market is the primary driver, contributing 70% of total revenue (INR 9,075 Cr in FY25). The US market accounts for 22% (INR 2,852 Cr), and the Rest of the World (ROW) contributes the remaining 8-10%.

Profitability Margins

Adjusted PAT margin improved from 14.3% in FY24 to 17.1% in FY25 (INR 2,215 Cr). This improvement was driven by a better product mix and cost control measures. Return on Capital Employed (ROCE) averaged 20% between FY20-FY24 and is projected to reach ~22% by FY27.

EBITDA Margin

EBITDA margin stood at 23.0% in Q2 FY26 (INR 920.8 Cr). The PBILDT margin improved by 520 bps in H1FY25 compared to the previous year, primarily due to benign raw material prices and rationalization of the product portfolio to focus on high-margin chronic therapies.

Capital Expenditure

Planned capital expenditure for FY26 is estimated at INR 700-750 Cr. This spending is intended for capacity maintenance and expansion into new segments like biosimilars and orthopedic implants, funded primarily through internal accruals.

Credit Rating & Borrowing

Maintains a strong credit profile with ratings of CRISIL AA+/Stable/A1+ and CARE AA+; Stable / CARE A1+. Total debt as of March 31, 2025, was INR 1,381 Cr, with an overall gearing ratio of 0.11x, indicating very low reliance on external debt.

⚙️ Operational Drivers

Raw Materials

Specific names not disclosed, but raw materials, freight, and input costs are cited as major margin drivers, with 'benign' pricing contributing to a 520 bps margin improvement in H1FY25.

Capacity Expansion

Operates 19 manufacturing facilities (18 in India, 1 in the US) and 4 R&D centers. A new CDMO plant for Enzene in the US recently became operational in September 2025, with a target revenue capacity of INR 300 Cr within 12-18 months.

Raw Material Costs

Raw material costs remained benign in H1FY25, supporting margin expansion. The company uses a strategy of rationalizing its product portfolio to offset input cost volatility and focus on higher-margin products.

Manufacturing Efficiency

Focusing on 'profitable growth' by rationalizing low-margin products. ROCE is expected to remain healthy at ~22% for FY25-FY27, reflecting efficient asset utilization.

Logistics & Distribution

Distribution is managed by a field force of over 12,000 medical representatives (MRs) and 8,000 stockists to ensure demand off-take for new and existing products.

📈 Strategic Growth

Expected Growth Rate

5-8%

Growth Strategy

Growth will be achieved by outperforming the Indian pharmaceutical market by 100-150 bps through new launches in chronic therapies (diabetes, oncology, neurology). Additionally, the company is scaling its US CDMO business (Enzene) and entering the orthopedic implant market to diversify revenue streams.

Products & Services

Pharmaceutical formulations in therapeutic areas including anti-infectives, gastroenterology, pain/analgesics, anti-diabetics, cardiology, oncology, dermatology, and biosimilars.

Brand Portfolio

Alkem (Parent Brand), Enzene (Biosimilars). Specific product brand names not listed in the provided text.

New Products/Services

Launched 4 products in the US in Q2 FY26. New CDMO operations in the US are expected to contribute INR 70-80 Cr in revenue for the current fiscal year.

Market Expansion

Expanding presence in regulated and semi-regulated markets including Australia, Chile, Philippines, Kazakhstan, and Europe. Target is to increase the share of international revenue beyond the current 30%.

Market Share & Ranking

Ranked 5th in the Indian pharmaceutical market according to IQVIA MAT March 2025.

🌍 External Factors

Industry Trends

The industry is shifting toward chronic therapies and biosimilars. Alkem is positioning itself by increasing its chronic segment sales force and investing in Enzene Bioscience to capture higher-growth biotech opportunities.

Competitive Landscape

Faces intense competition in the acute segment from other large Indian generic players, leading to pricing pressure.

Competitive Moat

Moat is built on a 50-year legacy, a dominant position in anti-infectives/gastro (Rank 5 in India), and a massive distribution network of 12,000+ MRs. This scale makes it difficult for new entrants to compete on distribution and brand recall.

Macro Economic Sensitivity

Sensitive to healthcare spending and inflation in raw material/freight costs, which impacted margins in previous years before normalizing in FY24.

Consumer Behavior

Increasing demand for chronic disease management (diabetes, heart health) is driving the company's shift in focus from acute to chronic therapies.

Geopolitical Risks

Operations in 40+ countries expose the company to changes in import/export policies and political conditions in key global markets.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA inspections (all sites currently have EIR) and Indian DPCO/NLEM price controls which affect ~30% of domestic revenue.

⚠️ Risk Analysis

Key Uncertainties

High dependence on the acute segment (80% of domestic sales) which is slower-growing and prone to price revisions. Regulatory risks from USFDA or Indian price control changes could impact margins by 2-3%.